We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock

Delisted

NBSE was delisted on the 10th of May, 2024.

56 hedge funds and large institutions have $59.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

14,400% more call options, than puts

Call options by funds: $145K | Put options by funds: $1K

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

21% more capital invested

Capital invested by funds: $49M → $59.3M (+$10.3M)

6% more funds holding

Funds holding: 5356 (+3)

Holders
56
Holders Change
+3
Holders Change %
+5.66%
% of All Funds
0.98%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
19
Reduced
15
Closed
8
Calls
$145K
Puts
$1K
Net Calls
+$144K
Net Calls Change
+$127K

NBSE Hedge Fund Activity: Q1 2021 in Review

56 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2021, worth a combined $59.3M — up 21% from $49M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NBSE positions and 8 closed out — a net gain of 3 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $5.75M. The largest seller was Renaissance Technologies, cutting an estimated $2.05M.

  • 56 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2021, up from 53 in Q4 2020.
  • Funds reported $59.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2021, up 21% quarter-over-quarter.
  • 11 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of +3 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2021 was Polar Asset Management Partners, an estimated $5.75M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2021 was Renaissance Technologies, an estimated $2.05M sold.

Based on aggregated 13F filings for Q1 2021.